Connection
Halis Akturk to Blood Glucose
This is a "connection" page, showing publications Halis Akturk has written about Blood Glucose.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
8.363 |
|
|
|
-
Akturk HK, Karakus KE, Chen B, Walker TC. Exploring the Relationship Between Newly Defined Continuous Glucose Monitoring (CGM) Metrics and the Standard CGM Metrics in 30,000 People with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):264-270.
Score: 0.457
-
Akturk HK, Karakus KE, Cengiz D, Mason E, Beck E, Kaur G, Garg SK. Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):193-200.
Score: 0.457
-
Akturk HK, Perkins BA, Dunn TC. Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring. Diabetes Technol Ther. 2025 11; 27(S4):S44-S50.
Score: 0.446
-
Mason E, Karakus KE, Akturk HK. Barriers to glucagon use in patients with type 1 diabetes. Prim Care Diabetes. 2025 06; 19(3):341-343.
Score: 0.428
-
Karakus KE, Snell-Bergeon J, Mason E, Akturk HK. Improvement in Newly Defined Continuous Glucose Monitor Metrics, Extended Hypoglycemia, and Extended Hyperglycemia With Automated Insulin Delivery Initiation in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 May; 20(3):721-726.
Score: 0.419
-
Karakus KE, Snell-Bergeon JK, Akturk HK. Comparison of Computational Statistical Packages for the Analysis of Continuous Glucose Monitoring Data with a Reference Software, "Ambulatory Glucose Profile," in Type 1 Diabetes. Diabetes Technol Ther. 2025 03; 27(3):202-208.
Score: 0.417
-
Akturk HK. Limitations of 14-Day Continuous Glucose Monitoring Sampling for Assessment of Hypoglycemia and Glycemic Variability in Type 1 Diabetes. Diabetes Technol Ther. 2024 07; 26(7):503-508.
Score: 0.396
-
Akturk HK, Sakamoto C, Vigers T, Shah VN, Pyle L. Minimum Sampling Duration for Continuous Glucose Monitoring Metrics to Achieve Representative Glycemic Outcomes in Suboptimal Continuous Glucose Monitor Use. J Diabetes Sci Technol. 2025 Mar; 19(2):345-351.
Score: 0.386
-
Polsky S, Akturk HK. Case series of a hybrid closed-loop system used in pregnancies in clinical practice. Diabetes Metab Res Rev. 2020 03; 36(3):e3248.
Score: 0.298
-
Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
Score: 0.272
-
Garg SK, Akturk HK. A New Era in Continuous Glucose Monitoring: Food and Drug Administration Creates a New Category of Factory-Calibrated Nonadjunctive, Interoperable Class II Medical Devices. Diabetes Technol Ther. 2018 06; 20(6):391-394.
Score: 0.267
-
Akturk HK, Rewers A, Joseph H, Schneider N, Garg SK. Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. Diabetes Technol Ther. 2018 06; 20(S2):S224-S232.
Score: 0.267
-
Garg SK, Akturk HK. The Future of Continuous Glucose Monitoring. Diabetes Technol Ther. 2017 06; 19(S3):S1-S2.
Score: 0.249
-
Garg SK, Akturk HK. Flash Glucose Monitoring: The Future Is Here. Diabetes Technol Ther. 2017 May; 19(S2):S1-S3.
Score: 0.248
-
Akturk HK, Mason E, Cengiz D, Karakus KE, Garg SK. Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2026 Jun; 28(6):614-618.
Score: 0.114
-
Umpierrez GE, Shah VN, Brady V, Clements MA, Espinoza J, Healey E, Kohn MA, Maahs DM, Oiknine R, Seley JJ, Weitzman SP, Kerr D, Akturk HK, Aleppo G, Al-Sofiani ME, Cengiz E, Doyle FJ, Ebekozien O, Edelman SV, Ekhlaspour L, Freckmann G, Heinemann L, Hirsch IB, Hsiao VC, Kim SH, Kovatchev B, Lal RA, Lind M, Mader JK, Mathioudakis N, McLaughlin T, Meo SA, Osafehinti DA, Phillip M, Prahalad P, Scheinker D, Snyder MP, Wang J, Wong JC, Wright EE, Shao MM, Scheideman AF, DuNova AY, Klonoff DC. Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report. J Diabetes Sci Technol. 2026 May; 20(3):695-707.
Score: 0.114
-
Riddell MC, Parkin CG, Turner LV, Akturk HK. Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations. Diabetes Technol Ther. 2026 Feb; 28(1_suppl):31S-37S.
Score: 0.114
-
Bergenstal RM, Heller A, Breton MD, Vigersky R, Brown SA, Forlenza GP, Sherr JL, Hovorka R, Russell SJ, Damiano ER, Putman MS, Beck RW, Renard E, Lal R, Cobelli C, Dassau E, Akturk HK, Weiss MA, Skyler JS. Evolution of the Artificial Pancreas: Components and Integration-CGMs, Insulin, and AP Systems. J Diabetes Sci Technol. 2025 07; 19(4):883-894.
Score: 0.109
-
Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025 07; 19(4):924-936.
Score: 0.109
-
Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. Diabetes Technol Ther. 2025 07; 27(S3):S48-S59.
Score: 0.109
-
Zahalka SJ, Akturk HK, Galindo RJ, Shah VN, Low Wang CC. Continuous Glucose Monitoring for Prediabetes: Roles, Evidence, and Gaps. Endocr Pract. 2025 Aug; 31(8):1054-1060.
Score: 0.108
-
Mann EA, Rompicherla S, Miyazaki B, Rioles N, Hardison H, Golden L, Sarhis J, Akturk HK, Lee J, DeSalvo DJ, Gomez P, Ebekozien O, Prahalad P. Early Continuous Glucose Monitor Use in Children and Adolescents With Type 1 Diabetes: Rates of Initiation and Impact on Glycemic Outcomes. Diabetes Care. 2025 May 01; 48(5):768-775.
Score: 0.108
-
Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 06; 27(6):430-438.
Score: 0.107
-
Klonoff DC, Freckmann G, Pleus S, Kovatchev BP, Kerr D, Tse CC, Li C, Agus MSD, Dungan K, Voglová Hagerf B, Krouwer JS, Lee WA, Misra S, Rhee SY, Sabharwal A, Seley JJ, Shah VN, Tran NK, Waki K, Worth C, Tian T, Aaron RE, Rutledge K, Ho CN, Ayers AT, Adler A, Ahn DT, Aktürk HK, Al-Sofiani ME, Bailey TS, Baker M, Bally L, Bannuru RR, Bauer EM, Bee YM, Blanchette JE, Cengiz E, Chase JG, Y Chen K, Cherñavvsky D, Clements M, Cote GL, Dhatariya KK, Drincic A, Ejskjaer N, Espinoza J, Fabris C, Fleming GA, Gabbay MAL, Galindo RJ, Gómez-Medina AM, Heinemann L, Hermanns N, Hoang T, Hussain S, Jacobs PG, Jendle J, Joshi SR, Koliwad SK, Lal RA, Leiter LA, Lind M, Mader JK, Maran A, Masharani U, Mathioudakis N, McShane M, Mehta C, Moon SJ, Nichols JH, O'Neal DN, Pasquel FJ, Peters AL, Pfützner A, Pop-Busui R, Ranjitkar P, Rhee CM, Sacks DB, Schmidt S, Schwaighofer SM, Sheng B, Simonson GD, Sode K, Spanakis EK, Spartano NL, Umpierrez GE, Vareth M, Vesper HW, Wang J, Wright E, Wu AHB, Yeshiwas S, Zilbermint M, Kohn MA. The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors. J Diabetes Sci Technol. 2024 11; 18(6):1346-1361.
Score: 0.104
-
Akturk HK, Bindal A. Advances in diabetes technology within the digital diabetes ecosystem. J Manag Care Spec Pharm. 2024 Oct; 30(10-b Suppl):S7-S20.
Score: 0.103
-
Hirsch IB, Beck RW, Marak MC, Calhoun P, Mottalib A, Salhin A, Manessis A, Coviello AD, Bhargava A, Thorsell A, Atakov Castillo A, Bode BW, Levister C, Levy CJ, Donahue C, Cordero C, Beatson C, Langel CR, Jacobson C, Kurek C, Cruse D, Pickering D, Tamarez D, Steenkamp DW, Desjardins D, Aleppo G, O'Malley G, Akturk HK, Diner J, Baran JD, Buse JB, Ruedy K, Codorniz K, Klein KR, Castorino K, Jordan LF, Kipnes M, Church MM, Hamdy O, Raskin P, Nguyen QT, Weinstock RS, Lee S, Rizvi S, Bzdick S, Ghorbani Rodriguez T, Salah T, Blevins T, Kudva YC, Haider Z. A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery. Diabetes Care. 2024 09 01; 47(9):1682-1687.
Score: 0.103
-
Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 06; 26(6):367-374.
Score: 0.100
-
Akturk HK, Michel K, Couts K, Karakus KE, Robinson W, Michels A. Routine Blood Glucose Monitoring Does Not Predict Onset of Immune Checkpoint Inhibitor-Induced Type 1 Diabetes. Diabetes Care. 2024 03 01; 47(3):e29-e30.
Score: 0.099
-
Akturk HK, Battelino T, Castañeda J, Arrieta A, van den Heuvel T, Cohen O. Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Technol Ther. 2024 03; 26(S3):102-106.
Score: 0.099
-
Shah VN, Akturk HK, Trahan A, Piquette N, Wheatcroft A, Schertz E, Carmello K, Mueller L, White K, Fu L, Sassan-Katchalski R, Messer LH, Habif S, Constantin A, Pinsker JE. Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology. J Diabetes Sci Technol. 2024 11; 18(6):1281-1287.
Score: 0.099
-
Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. 2025 Mar; 19(2):292-296.
Score: 0.099
-
Akturk HK, McKee AM. Emerging Technologies and Therapeutics for Type 1 Diabetes. Endocrinol Metab Clin North Am. 2024 03; 53(1):81-91.
Score: 0.096
-
Karakus KE, Shah VN, Klonoff D, Akturk HK. Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes. Diabetes Obes Metab. 2023 11; 25(11):3144-3151.
Score: 0.095
-
Akturk HK, Snell-Bergeon J, Shah VN. Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes. Diabetes Technol Ther. 2022 10; 24(10):779-783.
Score: 0.088
-
Akturk HK, Herrero P, Oliver N, Wise H, Eikermann E, Snell-Bergeon J, Shah VN. Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration. Diabetes Technol Ther. 2022 10; 24(10):749-753.
Score: 0.088
-
Akturk HK, Snell-Bergeon J, Shah VN. Health Care Professionals' Perspectives on Use of Diabetes Technologies for Managing Visually Impaired Patients With Diabetes. J Diabetes Sci Technol. 2023 11; 17(6):1610-1613.
Score: 0.088
-
Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022 03 01; 45(3):750-753.
Score: 0.087
-
Akturk HK, Vigers T, Forlenza G, Champakanath A, Pyle L. Comparison of Cgmanalysis, a Free Open-Source Continuous Glucose Monitoring Data Management and Analysis Software, with Commercially Available CGM Platforms: Data Standardization for Diabetes Technology Research. Diabetes Technol Ther. 2022 01; 24(1):54-60.
Score: 0.085
-
Akturk HK, Dowd R, Shankar K, Derdzinski M. Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features. Diabetes Technol Ther. 2021 03; 23(S1):S21-S26.
Score: 0.081
-
Acciaroli G, Welsh JB, Akturk HK. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022 05; 16(3):677-682.
Score: 0.080
-
Akturk HK, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes. Diabetes Technol Ther. 2021 01; 23(1):81-83.
Score: 0.077
-
Akturk HK, Brackett S. A Novel and Easy Method to Locate and Remove First Approved Long-Term Implantable Glucose Sensors. Diabetes Technol Ther. 2020 07; 22(7):538-540.
Score: 0.075
-
Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020 04; 22(4):583-589.
Score: 0.074
-
Akturk HK, Rewers A, Garg SK. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018 08; 25(4):246-250.
Score: 0.067
-
Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.
Score: 0.027
-
Hirsch IB, Beck RW, Marak MC, Kudva Y, Akturk HK, Bhargava A, Codorniz K, Diner J, Aleppo G, Blevins T, Levy CJ, Raskin P, Castorino K, Manessis A, Pickering D, Steenkamp DW, Weinstock RS, Bode BW, Hamdy O, Nguyen QT, Kipnes M, Ruedy KJ, Desjardins D, Haider Z, Jacobson C, Lee S, Buse JB, Klein KR, O'Malley G, Church MM, Mottalib A, Baran JD, Kurek C, Rizvi S, Donahue C, Tamarez D, Atakov Castillo A, Borgman S, Frey S, Calhoun P. A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes. Diabetes Care. 2025 Mar 01; 48(3):353-360.
Score: 0.027
-
Beck RW, Bailey RJ, Akturk HK, Rizvi S, Kudva Y, Blevins T, Church MM, Manessis A, Calhoun P, Ruedy KJ, Hirsch IB. A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 03; 27(3):161-169.
Score: 0.027
-
Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 01; 27(1):1-9.
Score: 0.026
-
Brown SA, Laffel LM, Akturk HK, Forlenza GP, Shah VN, Wadwa RP, Cobry EC, Isganaitis E, Schoelwer M, Lu VS, Rueda R, Sherer N, Corbett JP, Sasson-Katchalski R, Pinsker JE. Randomized, Crossover Trial of Control-IQ Technology with a Lower Treatment Range and a Modified Meal Bolus Module in Adults, Adolescents, Children, and Preschoolers with Varying Levels of Baseline Glycemic Control. Diabetes Technol Ther. 2025 03; 27(3):187-193.
Score: 0.026
-
Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.
Score: 0.025
-
Tian T, Aaron RE, DuNova AY, Jendle JH, Kerr D, Cengiz E, Drincic A, Pickup JC, Chen KY, Schwartz N, Muchmore DB, Akturk HK, Levy CJ, Schmidt S, Bellazzi R, Wu AHB, Spanakis EK, Najafi B, Chase JG, Seley JJ, Klonoff DC. Diabetes Technology Meeting 2023. J Diabetes Sci Technol. 2024 09; 18(5):1208-1244.
Score: 0.025
-
Carlson AL, Graham TE, Akturk HK, Liljenquist DR, Bergenstal RM, Sulik B, Shah VN, Sulik M, Zhao P, Briggs P, Sassan-Katchalski R, Pinsker JE. Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial. J Diabetes Sci Technol. 2024 11; 18(6):1288-1292.
Score: 0.025
-
Shah VN, Kanapka LG, Akturk HK, Polsky S, Forlenza GP, Kollman C, Beck RW, Snell-Bergeon JK. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study. Diabetes Technol Ther. 2024 04; 26(4):246-251.
Score: 0.025
-
Ebekozien O, Mungmode A, Sanchez J, Rompicherla S, Demeterco-Berggren C, Weinstock RS, Jacobsen LM, Davis G, McKee A, Akturk HK, Maahs DM, Kamboj MK. Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016-2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther. 2023 11; 25(11):765-773.
Score: 0.024
-
Karakus KE, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. Diabetes Care. 2023 09 01; 46(9):1646-1651.
Score: 0.024
-
Alonso GT, Triolo TM, Akturk HK, Pauley ME, Sobczak M, Forlenza GP, Sakamoto C, Pyle L, Frohnert BI. Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population. Diabetes Care. 2023 06 01; 46(6):1218-1222.
Score: 0.024
-
Shah VN, Akturk HK, Vigers T, Pyle L, Oliver N, Klonoff DC. Relationship Between Daytime Versus Nighttime Continuous Glucose Monitoring Metrics with A1C in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2023 01; 25(1):62-68.
Score: 0.023
-
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 10; 28(10):2092-2099.
Score: 0.023
-
Xu NY, Nguyen KT, DuBord AY, Pickup J, Sherr JL, Teymourian H, Cengiz E, Ginsberg BH, Cobelli C, Ahn D, Bellazzi R, Bequette BW, Gandrud Pickett L, Parks L, Spanakis EK, Masharani U, Akturk HK, Melish JS, Kim S, Kang GE, Klonoff DC. Diabetes Technology Meeting 2021. J Diabetes Sci Technol. 2022 07; 16(4):1016-1056.
Score: 0.022
-
Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 06; 24(6):373-380.
Score: 0.022
-
Garg SK, Liljenquist D, Bode B, Christiansen MP, Bailey TS, Brazg RL, Denham DS, Chang AR, Akturk HK, Dehennis A, Tweden KS, Kaufman FR. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technol Ther. 2022 02; 24(2):84-92.
Score: 0.021
-
Shah VN, Akturk HK, Joseph H, Schneider N, Snell-Bergeon JK. A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec. Diabetes Obes Metab. 2021 08; 23(8):1936-1941.
Score: 0.021
-
Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, Driscoll KA, Forlenza GP. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab. 2021 09; 23(9):2048-2057.
Score: 0.021
-
Kaur H, Schneider N, Pyle L, Campbell K, Akturk HK, Shah VN. Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis. Diabetes Technol Ther. 2019 12; 21(12):736-739.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|